Biomesina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biomesina

Quick Facts

Property Description
Active Ingredient Hyoscine Butylbromide
Form Tablet, Solution for Injection, Suppository
Pharmacological Class Antispasmodic (Spasmolytic)
General Purpose Relieves smooth muscle spasms
Origin Synthetic derivative of scopolamine

What Type of Medicine is Biomesina (Hyoscine Butylbromide)?

Biomesina is a commercially recognized medication with the active ingredient Hyoscine Butylbromide, classified as a potent antispasmodic whose primary purpose is to relieve acute pain caused by the tightening of internal smooth muscles. Mechanistically, the drug belongs to the class of peripheral anticholinergic agents (muscarinic antagonists), meaning it works by counteracting the activity of the chemical messenger acetylcholine in the body.

Hyoscine Butylbromide is categorized as a synthetic derivative originating from the natural tropane alkaloid scopolamine. Due to its quaternary ammonium compound structure, the medication is highly selective for the involuntary smooth muscles of the digestive, urinary, and biliary tracts. This selective targeting aids in the rapid, localized resolution of visceral cramping. This results in a peripheral action that minimizes its ability to cross the blood-brain barrier, which is a key differentiating feature from centrally acting anticholinergics.

The General Purpose and Forms of Biomesina

The general purpose of Biomesina is to promote smooth muscle relaxation to alleviate the painful, cramping spasms (spasmolysis) that occur in the abdomen and pelvis. This targeted action is used for managing discomfort arising from the over-activity of muscles within the walls of hollow internal organs. A typical neutral use scenario for this drug involves relieving the sharp discomfort of a biliary or renal colic episode.

As a single-ingredient product, Biomesina is manufactured in several dosage forms to suit different patient needs, including Oral Tablets for general use, Injection Solution for rapid parenteral (intravenous or intramuscular) administration in acute settings, and occasionally suppositories for rectal administration. The availability of these distinct pharmaceutical preparations ensures the medicine can be delivered based on the severity and urgency of the spasmodic episode.

Regulatory References

  1. WHO Essential Medicines List for Hyoscine Butylbromide
  2. WHO Essential Medicines List Entry

What side effects are possible with Biomesina?

Possible side effects and safety information

The safety profile of Biomesina (Hyoscine Butylbromide) is based on adverse reactions officially documented in regulatory labels, which are generally associated with its peripheral anticholinergic properties.

Adverse reactions are classified by frequency according to standard regulatory terminology (e.g., EMA/ICH guidelines):

Classification Representative Adverse Reactions
Common Tachycardia (increased heart rate), Dry mouth, Accommodation disorders (difficulty focusing), Dizziness.
Rare Urinary retention.
Not Known Anaphylactic shock, Anaphylactic reactions, Dyspnoea (shortness of breath), Hypotension (decreased blood pressure), Mydriasis (dilated pupils).

These effects are grouped into System-Organ Classes, including Cardiac Disorders, Eye Disorders, Gastrointestinal Disorders, and Immune System Disorders.

Serious Adverse Reactions and Safety Restrictions

Official regulatory documents classify anaphylactic shock (including fatal cases) and anaphylactic reactions as serious adverse reactions. Certain effects, such as hypotension and tachycardia, are noted to be particularly relevant following the injection form and require caution in individuals with underlying cardiac disease.

The medicine is strictly contraindicated by regulatory bodies in patients with pre-existing conditions that are sensitive to anticholinergic effects, such as narrow-angle glaucoma, myasthenia gravis, megacolon, and urinary retention due to prostatic enlargement. This ensures that the use of the medication does not critically aggravate these conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that an overdose of Biomesina (Hyoscine Butylbromide) primarily manifests as an exaggeration of the drug's known peripheral anticholinergic effects. While serious signs of poisoning have not been commonly observed in human acute cases, the potential for severe, life-threatening outcomes mandates strict adherence to official emergency guidance.

Documented Clinical Manifestations and Severity

Overdose signs documented in regulatory labeling include tachycardia (fast heart rate), dry mouth, urinary retention, reddening of the skin, and transient visual disturbances. Severe outcomes that have been associated with over-exposure include respiratory paralysis and serious cardiovascular complications. Furthermore, central nervous system effects such as confusion or other psychiatric disorders cannot be totally ruled out under certain circumstances.

Emergency Actions Required

Immediate medical attention must be sought if any severe symptoms indicative of overdose occur. Specifically, urgent ophthalmological advice is required if a painful, red eye accompanied by a loss of vision develops.

Management measures described in official labeling focus on supportive care. Symptoms are known to respond to agents in the class of parasympathomimetics. Procedures such as gastric lavage or the administration of activated charcoal are described for oral overdose. Intervention for severe effects may require intubation and artificial respiration for paralysis or catheterization for urinary retention.

Therapeutic Uses of Biomesina

What Biomesina Treats: Main Uses and Benefits

Biomesina is indicated for the symptomatic management of conditions associated with painful spasms in the abdominal and pelvic areas. This medicine is used to help manage the temporary discomfort caused by involuntary muscle contractions in the digestive and urinary systems. Common clinical scenarios involve the symptomatic relief of acute pain from renal colic, spasms related to biliary tract disorders, and pain from gastrointestinal spasms.

The essential benefit is focused on helping to alleviate the acute and disruptive pain associated with these spasms, which may offer temporary comfort and support daily activities.


Quick Fact Block

Quick Fact: Relief for Acute Spasmodic Pain


Eligibility and Restrictions for Use

The eligibility for using Biomesina is defined by government regulatory documents based on pre-existing conditions, age, and physiological state. The medicine is contraindicated and must not be used in specific populations, including patients with untreated narrow-angle glaucoma, myasthenia gravis, megacolon, or pre-existing tachycardia. Use is also prohibited in the presence of obstructive uropathy (such as prostatic hypertrophy leading to urinary retention) and any form of mechanical stenosis or paralytic ileus within the gastrointestinal tract.

For age-related eligibility, the oral tablet formulation is not recommended for children under 6 years of age, though it is generally permitted for adults and adolescents. Regarding reproductive status, use is not recommended during both pregnancy and lactation (breastfeeding) as a precautionary measure due to a lack of sufficient human data. Special caution is advised for patients with existing cardiac conditions, and the injectable form must not be administered intramuscularly to individuals taking anticoagulant medication. This structured regulatory profile strictly outlines who can or cannot use the medicine.

What should I know about interactions with other medicines?

Biomesina Interactions with other medicines and products

The official regulatory profile for Biomesina (Hyoscine Butylbromide) details interactions that primarily stem from pharmacodynamic reinforcement, affecting the co-administration of certain drug classes and specific physical administration routes.

️ Contraindicated Combinations and Administration Restrictions

Interacting Substance Official Restriction Context
Anticoagulant Drugs Prohibited for intramuscular injection. Avoids the risk of intramuscular haematoma; other routes must be used.
Oral Tablets (Excipients) Contraindicated in patients with hereditary fructose or galactose intolerances. Due to the presence of lactose and sucrose in the formulation.

Pharmacodynamic Effects

Co-administration with several classes of medicines may intensify the peripheral anticholinergic effects of Biomesina, a pattern established in official regulatory documents. These classes include:

  • Other Anticholinergic Agents, including Tricyclic and Tetracyclic Antidepressants, and certain Antihistamines and Antipsychotics.
  • The chronotropic action (effect on heart rate) of Beta-adrenergic agents may also be enhanced.

Conversely, medicines classified as Dopamine Antagonists (e.g., Metoclopramide and Domperidone) may result in a diminution (decrease) of the gastrointestinal effects of Biomesina.


Other Documented Constraints

For medicines like Antacids or Adsorbent Anti-diarrhoeals, a time separation of at least one hour between doses may be required. Patients should be aware that consuming Alcohol may increase the chance of experiencing side effects such as drowsiness. Caution is officially advised with the parenteral (injectable) route in patients with cardiac conditions due to the potential for enhanced tachycardia and hypotension.

Mechanism of Action

Targeting the Cholinergic Signaling Pathway

The mechanism of action for Hyoscine Butylbromide involves its interaction with nerve signaling pathways that regulate involuntary smooth muscle contraction. The drug functions as a competitive antagonist primarily at the Muscarinic Acetylcholine Receptors ( mAChRs), specifically the M2 and M3 subtypes on smooth muscle cells. By occupying the binding site of the endogenous neurotransmitter Acetylcholine ( ACh), the drug suppresses excitatory impulses originating from the parasympathetic system, thereby interfering with the signal cascade responsible for initiating muscle contraction.

Inhibition of Intracellular Contraction Signals

Antagonism of the mAChR (specifically the M3 subtype) modulates the subsequent Gq protein activation, thereby limiting the mobilization of calcium ions ( Ca^2+) inside the smooth muscle cells. Since the increase in cytosolic Ca^2+ is a required step for muscle contraction, its limitation causes a decrease in muscle tension. The resulting physiological effect is spasmolysis, characterized by a decrease in involuntary smooth muscle motility.

Peripheral Selectivity and Visceral Focus

The drug's structure as a quaternary ammonium compound limits its ability to cross the highly selective Blood-Brain Barrier ( BBB). This chemical constraint restricts its interaction primarily to the body's periphery—the smooth muscles of the digestive, biliary, and urogenital tracts. This mechanism results in activity focused on the modulation of muscle tone in the viscera.

Dosage and Administration Information

How to Use Biomesina

Biomesina (Hyoscine Butylbromide) is administered following protocols focused on the route, frequency, and duration of use. The medicine is utilized in two primary ways: orally, which is for non-acute use, and parenterally (by intravenous, intramuscular, or subcutaneous injection) for rapid administration in acute clinical settings.


Routes, Dosing, and Frequency

Administration Route Standard Adult Dosing Regimen Frequency and Constraints
Oral (Tablets) 10 mg or 20 mg per dose Up to 4 times daily, not to exceed 80 mg total per day. Can be taken with or without food.
Parenteral (Injection) A single 20 mg dose The dose may be repeated once after a 30-minute interval, with a maximum total limit of 100 mg per day. Intravenous administration is performed slowly.

Administration Context and Duration

Tablets are swallowed whole with an adequate amount of water. For the pediatric population aged 6 to 12 years, the oral regimen is standardized to 10 mg taken three times daily. Use in children under 6 years is not recommended.

The usage of Biomesina is for short-term application. The drug is not intended for continuous daily consumption or long-term administration without professional re-evaluation of the underlying cause of pain. Furthermore, the intramuscular injection route is avoided for patients receiving anticoagulation therapy; instead, the intravenous or subcutaneous routes are utilized to prevent procedural complications.

Recent Clinical Evidence

Research evidence / Overview of studies for Biomesina (Hyoscine Butylbromide)

Research related to Biomesina (Hyoscine Butylbromide) was conducted to examine symptom patterns associated with general abdominal and intestinal cramping. The evidence base consists of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses, designed to explore short-term changes in patient-reported outcomes describing perceived discomfort. Research highlights changes measured over brief follow-up durations (typically minutes to a few hours). While the structural evidence is extensive for acute relief, research provides limited insight into the drug's role in the long-term management of recurrent pain.

Research Findings for Specific Indications

Studies exploring the use of Biomesina for Irritable Bowel Syndrome (IBS) pain consist of controlled trials and systematic reviews, which examined outcomes related to physical discomfort and global symptom improvement. While patterns were observed, the certainty remains low in some comprehensive reviews due to data heterogeneity and potential risk of bias.

For acute episodes, such as renal or biliary colic, evidence comes from acute-setting RCTs that monitored changes in acute pain scores and the need for rescue analgesia. The structural research base in this area is observed to be limited compared to the research base for functional pain, with one key limitation being that sample sizes were modest in many trials.

Research has also examined the medicine during specific diagnostic and therapeutic procedures to measure the reduction in smooth muscle motility. However, findings were conflicting across meta-analyses regarding the medicine's association with changes in key diagnostic performance metrics, and the inconsistency of results means its role remains uncertain.

Evidence in Special Populations and Limitations

Research has examined the medicine in populations outside of the general adult demographic. Data for certain groups remain insufficient for high-quality assessment in children and adolescents. Research explored the medicine's use in pregnant women, examining outcomes during labor, but findings were highly heterogeneous and evidence is limited. In general, the short-term focus of the majority of the existing research means long-term effects are not fully established, and comparative evidence is lacking for several clinical indications.

Frequently Asked Questions (FAQ)

Common questions about Biomesina (FAQ)


Q: How quickly does Biomesina start working for stomach cramps?

A: According to official product information, Hyoscine Butylbromide is described as having a rapid onset of action, particularly when administered by injection for acute clinical settings. While the regulatory documents confirm its fast action against spasms, specific time frames (e.g., in minutes) for the oral tablet form are typically not defined in the official Summaries of Product Characteristics.

Q: What is the longest I can expect the relief from Biomesina to last?

A: The recommended dosing frequency for oral tablets, which is typically up to four times daily, provides an indication of the expected duration of the medicine's effects. The actual length of relief can vary among individuals based on the patient's individual body chemistry and the severity of the spasm.

Q: What should I do if I forget to take a dose of Biomesina?

A: Official patient information describes that a missed dose may be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose is typically skipped, and the regular schedule is continued. Patients are advised not to take a double dose to compensate for a forgotten one.

Q: Can older people or the elderly safely use Biomesina for cramps?

A: Regulatory documents state that due to the medicine's properties, caution is described for use in the elderly, particularly those prone to conditions such as prostate enlargement that may lead to urinary retention. Although older patients have been included in clinical trials, specific safety considerations should be reviewed.

Q: How long does the body take to completely clear Biomesina after the last dose?

A: Pharmacokinetic data from regulatory sources indicate that the terminal half-life of the active ingredient for the injection form is approximately five hours. This is the time the body takes to eliminate half of the drug. Around 50% of the unchanged active ingredient is typically excreted via the renal route (kidneys).

Q: Can Biomesina be used to help with period pain and menstrual cramps?

A: Official drug indications in various regions describe the use of Hyoscine Butylbromide for spastic pain associated with functional disorders in the female genital organs, which includes painful periods (dysmenorrhoea). The medicine works by relaxing the smooth muscle in the abdominal and pelvic region.

Q: How does Biomesina affect the digestive system besides reducing spasms?

A: The mechanism of Biomesina, which blocks certain chemical signals, can lead to other effects on the body. Officially reported adverse effects on the digestive system or related systems include commonly occurring dry mouth and, less commonly, the potential for constipation.

Q: Does Biomesina have any known effects on my ability to drive?

A: Due to common side effects listed in regulatory documents, such as dizziness and accommodation disorder (which is difficulty focusing your eyes), patients are cautioned. If these effects are experienced, it is advised to avoid driving or operating potentially hazardous machinery.

Q: Why is Biomesina sometimes prescribed for colic pain?

A: Biomesina is officially indicated for the treatment of acute muscular spasms in the abdomen and pelvis. This mechanism of relaxing smooth muscles makes it effective for managing the severe, cramping pain associated with conditions like renal colic (kidney stones) or biliary colic (gallbladder issues).

Q: Can Biomesina be used for pain that is not related to spasms or cramps?

A: The drug is pharmacologically classified as an antispasmodic agent, and its mechanism of action is limited to relaxing the involuntary smooth muscles of the digestive, urinary, and biliary tracts. Its primary regulatory use is for the relief of pain that is specifically caused by these muscular spasms.

Q: Is Biomesina a strong pain reliever, or more for mild discomfort?

A: Biomesina’s effect is specifically on the cause of the pain, which is acute smooth muscle spasm. It is used to relieve the intense, acute pain associated with conditions like renal or biliary colic. However, official regulatory labels do not formally classify its overall analgesic strength as 'strong' or 'mild' when compared to other non-spasm-specific pain relievers.

Q: What are the signs of a non-allergic hypersensitivity reaction to Biomesina?

A: Signs of officially reported, non-life-threatening hypersensitivity reactions include skin issues such as urticaria (hives/nettle rash), a general rash, skin redness (erythema), and itching (pruritus). More serious immune reactions, including anaphylaxis, have been noted in regulatory documentation.

Q: What ingredient in Biomesina Compuesta is for general pain and fever?

A: The combination formulation, often marketed as 'Biomesina Compuesta' or 'Buscopan Plus' in various regions, includes an additional active ingredient, typically Paracetamol (Acetaminophen). This second component is included specifically to provide general pain relief and reduce fever.

Q: Why do some people use Biomesina for pain other than stomach or kidney colic?

A: Official indications for the medicine extend beyond just colic pain. It is also used in specific medical settings, such as radiology for better image quality, or in other diagnostic procedures like a gastroduodenal endoscopy, where the goal is to reduce unwanted spasm and relax the smooth muscle.

Q: Can Biomesina be used by people who have irritable bowel syndrome (IBS)?

A: Official indications in some jurisdictions state that Hyoscine Butylbromide is used for the relief of abdominal pain associated with Irritable Bowel Syndrome (IBS). It works by helping to relax the involuntary spasms in the digestive tract that cause discomfort.

Q: Is Biomesina effective for muscle spasms in the back or limbs?

A: Official pharmacological data explains that Biomesina is a peripheral anticholinergic agent with activity focused on the viscera, which means the smooth muscles of the internal organs (digestive, urinary, and biliary tracts). Its mechanism is not designed to target the skeletal muscles found in the back or limbs.

Q: Why does Biomesina sometimes come as a 'Compuesta' version?

A: The 'Compuesta' (meaning 'compound' or 'plus') formulation is created to offer a combined therapeutic effect. It includes the spasm-relieving agent, Hyoscine Butylbromide, alongside a general pain reliever like Paracetamol, providing relief for both spasm and non-spasm-related pain simultaneously.

Q: What should I know about using Biomesina if I have an enlarged prostate?

A: It is officially stated that Biomesina is contraindicated and should not be used if a patient's enlarged prostate has led to a condition called urinary retention (the inability to pass urine). This is because the medicine's properties can potentially aggravate this condition.

Q: Is it safe to take Biomesina on an empty stomach?

A: Official patient information confirms that the tablets can generally be taken with or without food. There are no specific safety restrictions or regulatory requirements mandating that the medicine must be taken alongside a meal to ensure safety or efficacy.

Q: Is it okay to take Biomesina with alcohol?

A: Regulatory guidance includes a caution regarding the use of alcohol while taking this medication. This is because alcohol may increase the likelihood of experiencing central nervous system side effects such as drowsiness.

Q: Does Biomesina have any anti-inflammatory properties at all?

A: Based on regulatory pharmacological data, Biomesina is classified as a purely antispasmodic agent (smooth muscle relaxant) with a mechanism of action centered on blocking certain nerve signals. The official product profile does not list any anti-inflammatory properties.

Q: Can I take Biomesina if I have asthma or breathing issues?

A: While asthma is not a contraindication, the serious adverse reactions section lists dyspnoea (shortness of breath) as a possible effect, particularly following the injection form. The use of the medicine in patients with pre-existing breathing issues is generally subject to review by a healthcare professional.

Q: Does Biomesina affect the kidneys or liver?

A: The active ingredient is partly excreted via the renal route (kidneys). For combination products used over a long period, official labels may advise monitoring renal and liver function. This suggests that while effects are possible with prolonged use, the single-ingredient product is primarily cleared by the kidneys.

Q: Is there a maximum number of days I can safely take Biomesina?

A: Regulatory information clearly states that the medicine is not intended for use on a continuous daily basis or for extended periods without a re-evaluation of the underlying cause of the pain. The maximum short-term use varies; for some non-prescription combination products, use is typically limited to three days.

Q: Why is Biomesina considered an anticholinergic drug?

A: Biomesina is classified as an anticholinergic drug because it acts as a competitive antagonist at the Muscarinic Acetylcholine Receptors ( mAChRs) in the body. This means it blocks the action of the natural chemical messenger Acetylcholine, which is responsible for stimulating muscle contractions.

How should Biomesina be stored and disposed of?

How to Store and Dispose of Biomesina

Official regulatory documents define strict conditions for the storage and disposal of Biomesina (Hyoscine Butylbromide).


Storage Requirements

Biomesina must be stored at a temperature not exceeding 30 C, kept in a dry place, and protected from light. The medicine is required to be stored out of the sight and reach of children.

For the injection solution, the regulatory label mandates that it must be used immediately after opening the ampoule, and any unused portion must be discarded.


Disposal Instructions

Unused or expired Biomesina must not be thrown away via wastewater or household waste. Disposal instructions require returning the medicine to a pharmacist to ensure it is disposed of correctly in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biomesina found in:

A-Z Index: